SP-3164 for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral drug called SP-3164 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least 2 prior treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell non-Hodgkin lymphoma (like DLBCL, mantle cell lymphoma, follicular lymphoma, or marginal zone lymphoma) that has come back or not responded to treatment.
- You have already received at least 2 different types of therapy for your lymphoma.
- You have a tumor sample from a biopsy within the last 2 years, or you are willing to have a new biopsy.
- You are physically active enough to do light work or be up and about (ECOG score 0 or 1).
- Your heart, liver, kidney, and bone marrow function are within normal limits, and you can take oral medication.
- You do not have other serious medical conditions like active infections, recent major surgery, or certain heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This early-phase study tests a new treatment called STR-P004 for people with certain aggressive B-cell lymphomas that have not responded to or returned after two or more prior treatments. The goal is to see if it is safe and effective.
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
This trial tests a new drug called STR-P004 for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and can help fight the cancer.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Hear when a new Lymphoma, Non-Hodgkin's, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.